Meeting
2021 Genitourinary Cancers Symposium
The effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitor (ICI) efficacy in patients with metastatic urothelial carcinoma (mUC) in real-world setting.
Authors
Shilpa Gupta
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Shilpa Gupta , Mohammad Siddique Khan , Nathan Radakovich , Wei Wei , Moshe Chaim Ornstein , Timothy D. Gilligan , Omar Y. Mian , Scott Dawsey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 417)
DOI
10.1200/JCO.2021.39.6_suppl.417
Abstract #
417
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The effect of antibiotic (Abx) use on immune checkpoint inhibitor (ICI) efficacy in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Ubenthira Patgunarajah
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of type of antibiotics (Abx) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Charbel Hobeika
Poster
2019 Gastrointestinal Cancers Symposium
Impact of antibiotic use on response to treatment with immune checkpoint inhibitors.
First Author: Uqba Khan
Poster
2024 ASCO Annual Meeting
Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).
First Author: Michal Sternschuss